Rectal Chlamydia Test in Kathmandu Site-Matched NAAT — Extragenital Infection Testing
Rectal chlamydia is a common but often missed extragenital infection, especially in MSM and people with receptive anal sex. Site-matched NAAT testing at Thamel Clinic detects what urine tests miss.
Medically Reviewed Content
Reviewed by: Thamel Clinic Clinical Team (MBBS, MD)
Last medical review: November 8, 2026
Next scheduled review: May 8, 2027
This content follows evidence-based medical guidelines and is regularly updated to reflect current medical practices.
Important Safety Information
- Urine testing does not detect rectal chlamydia — if you have had receptive anal sex, specifically request rectal swab testing.
- Doxycycline is preferred over azithromycin for rectal chlamydia — inferior treatment leads to persistent infection.
- Test-of-cure is recommended for rectal infection — persistent symptoms or risk require repeat testing.
- All partners must be tested and treated — asymptomatic partners perpetuate the infection cycle.
- Rectal chlamydia increases HIV susceptibility — complete STI screening including HIV is important.
Rectal Chlamydia in Kathmandu
- MSM health services — MSM populations in Kathmandu face significant barriers to sexual health care including stigma; confidential, non-judgmental services are essential for this population.
- Testing gaps — Many clinics in Nepal offer only urine or genital chlamydia testing; rectal and pharyngeal site-specific testing is less commonly available, leading to missed extragenital infections.
- NAAT availability — NAAT technology is available at better-equipped laboratories in Kathmandu; the key is requesting site-matched sampling rather than assuming urine covers all sites.
- Stigma barriers — MSM individuals and people with receptive anal sex often delay seeking care due to stigma; confidential private clinics reduce this barrier.
- Treatment access — Doxycycline and azithromycin are widely available in Nepal; correct agent selection (doxycycline for rectal) is the clinical issue, not drug availability.
- Partner notification — Partner notification for extragenital infections is particularly challenging due to stigma; supportive counseling helps patients navigate disclosure.
Overview of Rectal Chlamydia
Rectal chlamydia is infection of the rectal mucosa with Chlamydia trachomatis, acquired through receptive anal intercourse. It is classified as an extragenital infection — meaning it occurs outside the genital tract — and is one of the most commonly missed STIs because it causes no symptoms in the majority of cases and is invisible to standard urine or genital testing.
The epidemiology is concentrated in specific populations: men who have sex with men (MSM), people with receptive anal intercourse regardless of gender identity, and partners of people with genital chlamydia. Studies consistently show that rectal chlamydia is predominantly asymptomatic — estimates suggest 85% or more of rectal infections cause no symptoms — yet they persist as infectious reservoirs.
The diagnostic challenge is anatomical. Chlamydia NAAT performed on urine detects only urogenital infection. A person with rectal chlamydia and no urethral infection will test negative on urine — giving false reassurance while the rectal infection persists and is transmitted to partners. Correct diagnosis requires a rectal swab NAAT, collected from the correct anatomical site.
Treatment of rectal chlamydia differs from genital infection. Doxycycline is preferred over azithromycin for rectal infection because azithromycin has inferior efficacy at this site. Test-of-cure is recommended after treatment for rectal chlamydia. At Thamel Clinic, site-matched testing, correct treatment and partner management are provided with complete confidentiality.
What Is Rectal Chlamydia?
Rectal chlamydia is infection of the rectal lining (mucosa) with Chlamydia trachomatis — the same bacterium that causes genital chlamydia, but at a different anatomical site. It is acquired through receptive anal intercourse, where the bacterium infects the rectal mucosa directly.
The infection is classified as extragenital because it occurs outside the genital tract. This classification matters clinically because it affects both testing (needs site-specific sampling) and treatment (doxycycline preferred over azithromycin). Rectal chlamydia can occur with or without concurrent genital infection — they are independent infections at different sites.
Rectal chlamydia is overwhelmingly asymptomatic. Most infected individuals have no discharge, pain or other symptoms. When symptoms do occur, they include rectal discharge, pain during defecation, rectal bleeding, itching and tenesmus (feeling of incomplete evacuation). The absence of symptoms does not mean absence of infection — asymptomatic rectal chlamydia still transmits to partners and can cause complications.
- Infection of rectal mucosa with Chlamydia trachomatis
- Acquired through receptive anal intercourse
- Extragenital infection — outside the genital tract
- Usually asymptomatic — silent reservoir of infection
- Independent of genital infection — can occur alone or together
- Still transmits to partners despite no symptoms
Same bacterium
Chlamydia trachomatis — the same organism as genital chlamydia, different site.
How it spreads
Receptive anal intercourse transmits the bacterium to rectal mucosa.
Silent infection
Most cases have no symptoms — yet remain infectious to partners.
Site independence
Rectal and genital infections are separate — one does not imply the other.
Who Needs Rectal Testing?
Rectal chlamydia testing is indicated for anyone who has had receptive anal intercourse — this includes MSM and anyone else with anal receptive sex, regardless of gender identity or sexual orientation. The exposure history determines the need for site-specific testing, not the patient’s identity category.
Partners of people diagnosed with genital or rectal chlamydia should be tested at all relevant sites based on their exposures. If a partner has had receptive anal sex, rectal testing is indicated even if they have no symptoms.
People who have had receptive anal sex should also be tested for other extragenital infections — rectal gonorrhoea, pharyngeal chlamydia and gonorrhoea — because these infections cluster. A complete extragenital screen covers all sites of potential infection rather than testing for one organism at one site.
- Anyone with receptive anal intercourse — MSM and others
- Partners of diagnosed chlamydia cases with anal exposures
- People with rectal symptoms — discharge, pain, bleeding, itching
- Screening for extragenital infections alongside genital testing
- Periodic screening for sexually active people with ongoing risk
Exposure-based
Receptive anal intercourse is the indication — identity category is irrelevant.
Partner testing
Partners need site-matched testing based on their own exposures.
Complete screening
Rectal chlamydia rarely travels alone — test for gonorrhoea and pharyngeal infections too.
Routine screening
Periodic screening for people with ongoing receptive anal sex exposures.
How Rectal Chlamydia Testing Works
Rectal chlamydia testing uses NAAT — the same molecular technology as genital testing — but performed on a rectal swab rather than urine. The swab collects cells from the rectal lining where the bacterium resides. The patient or clinician collects the swab approximately 3–5 cm into the rectum, rotating gently to sample the mucosa.
Self-collection is possible and acceptable — many patients prefer to collect their own swab privately. The technique is simple and NAAT is highly sensitive and specific for rectal specimens. Results are typically available within 1–3 working days.
Critically, urine testing does not detect rectal chlamydia. A urine NAAT only samples the urogenital tract. A person with isolated rectal infection will test negative on urine — giving false reassurance. This is why site-matched testing based on actual exposures is essential: the test must sample the site where exposure occurred.
- Rectal swab NAAT — same technology as genital testing, different site
- Swab inserted 3–5 cm into rectum, rotated gently
- Self-collection possible and acceptable — private option available
- Results within 1–3 working days typically
- Urine testing does NOT detect rectal infection — site-matched sampling essential
- High sensitivity and specificity for rectal specimens
Rectal swab
NAAT on rectal cells — the correct test for rectal infection.
Self-collection
Patients can collect their own swab privately — simple and acceptable.
Urine misses it
Urine NAAT only detects urogenital infection — rectal needs its own swab.
Site-matched
The test must match the exposure site — this is the key to not missing infection.
Treatment: Doxycycline Preferred
Rectal chlamydia is treated with antibiotics, but the choice differs from genital infection. Doxycycline (100 mg twice daily for 7 days) is the preferred treatment for rectal chlamydia because azithromycin has inferior efficacy at this anatomical site. This is a key clinical distinction that affects cure rates.
Test-of-cure is recommended for rectal chlamydia — a repeat NAAT approximately 4 weeks after treatment completion confirms eradication. This is more important for rectal than genital infection because of the higher treatment failure rates with azithromycin and the persistent asymptomatic nature of the infection.
All sexual partners must be tested and treated to prevent reinfection. Partners should abstain from sex until both complete treatment. If reinfection occurs, it usually indicates an untreated partner rather than treatment failure — partner management is critical.
- Doxycycline 100mg twice daily for 7 days — preferred for rectal infection
- Azithromycin has inferior efficacy for rectal chlamydia — avoid if possible
- Test-of-cure recommended ~4 weeks after treatment
- All partners tested and treated to prevent reinfection
- Abstain from sex until both partners complete treatment
Doxycycline
Preferred for rectal infection — 7-day course with superior efficacy.
Azithromycin caution
Inferior for rectal site — doxycycline is the better choice.
Test-of-cure
Repeat NAAT at ~4 weeks confirms eradication — recommended for rectal infection.
Partner management
Simultaneous partner treatment prevents the reinfection cycle.
Complications and Why Testing Matters
Rectal chlamydia causes local inflammation that can lead to proctitis — inflammation of the rectal lining causing pain, discharge and bleeding. Untreated, it can contribute to the development of lymphogranuloma venereum (LGV) — a more invasive form caused by specific chlamydia serovars — though LGV is less common.
The infection also increases susceptibility to HIV transmission and acquisition. Rectal mucosa is particularly vulnerable to HIV because of its cellular structure and high concentration of immune cells. Untreated chlamydia creates an inflammatory environment that facilitates HIV transmission — making detection and treatment important for HIV prevention.
Asymptomatic rectal chlamydia serves as a hidden reservoir — infecting partners who may then develop genital infections or transmit further. The silent nature means many infections persist for months, spreading through sexual networks undetected. Site-matched testing is the only way to identify and interrupt this transmission.
- Can cause proctitis — rectal inflammation with pain and discharge
- Increases HIV susceptibility and transmission risk
- LGV (lymphogranuloma venereum) is a more invasive chlamydia form
- Asymptomatic reservoir — silently transmits to partners
- Persistent infection without treatment spreads through networks
Proctitis
Rectal inflammation causing pain, discharge and bleeding — treatable once diagnosed.
HIV risk
Rectal chlamydia increases HIV acquisition and transmission — treatment reduces this.
LGV potential
Specific chlamydia serovars can cause more invasive LGV — needs appropriate treatment.
Hidden reservoir
Asymptomatic infection silently spreads — site-matched testing interrupts transmission.
Complete Extragenital Screening
Rectal chlamydia rarely occurs in isolation. People with receptive anal sex are also at risk for rectal gonorrhoea, pharyngeal (throat) chlamydia and gonorrhoea, and genital infections. A complete extragenital screen tests all relevant sites for all relevant organisms rather than assuming one test covers everything.
A typical complete screen for someone with receptive anal and oral sex includes: rectal NAAT for chlamydia and gonorrhoea, pharyngeal NAAT for chlamydia and gonorrhoea, urine or genital NAAT for chlamydia and gonorrhoea, plus serology for HIV, syphilis and hepatitis. This comprehensive approach catches infections that single-site or single-organism testing misses.
The goal is not just finding infection but understanding the full picture — which sites are infected, which organisms are present, and what treatment is needed. This informs correct treatment (doxycycline for rectal chlamydia) and complete partner management.
- Rectal chlamydia + gonorrhoea NAAT
- Pharyngeal chlamydia + gonorrhoea NAAT
- Urogenital chlamydia + gonorrhoea NAAT
- HIV, syphilis and hepatitis serology
- Complete picture enables correct treatment and partner management
All sites
Rectal, pharyngeal and urogenital — each site tested based on actual exposures.
All organisms
Chlamydia and gonorrhoea at each site, plus viral serology.
Infections cluster
Extragenital infections travel together — complete screening catches what partial testing misses.
Informed treatment
Knowing all infections present enables correct treatment for each.
Rectal Chlamydia Testing & Costs
| Service | What It Includes | Cost (NPR) |
|---|---|---|
| Confidential consultation | Exposure assessment and testing plan — MSM-inclusive, non-judgmental | Rs. 450 |
| Rectal chlamydia NAAT | Site-matched NAAT for Chlamydia trachomatis from rectal swab | Rs. 2,000–3,500 |
| Rectal gonorrhoea NAAT | Site-matched NAAT for Neisseria gonorrhoeae | Rs. 2,000–3,500 |
| Pharyngeal NAAT panel | Throat swab for chlamydia and gonorrhoea | Rs. 3,000–5,000 |
| Complete extragenital screen | Rectal + pharyngeal + urogenital NAAT plus HIV/syphilis/hepatitis | Rs. 6,000–9,000 |
| Doxycycline treatment | 7-day course — preferred for rectal infection | Rs. 500–1,000 |
| Test-of-cure retest | Repeat rectal NAAT ~4 weeks after treatment | Rs. 2,000–3,500 |
Indicative NPR pricing; confirm current rates when booking. Self-collection option available.
Why Patients Choose Thamel Clinic for Rectal Testing
- Site-matched testing — rectal, pharyngeal and urogenital swabs based on actual exposures, not urine alone.
- MSM-inclusive care — confidential, non-judgmental service for MSM and all patients.
- Correct treatment — doxycycline preferred for rectal chlamydia, not inferior azithromycin.
- Complete screening — extragenital infections tested together, not in isolation.
- Test-of-cure — repeat NAAT recommended for rectal infection to confirm eradication.
- Partner management — guidance for partner testing and treatment to prevent reinfection.
- Self-collection option — patients can collect their own swab privately if preferred.
Frequently Asked Questions
What is rectal chlamydia?
Rectal chlamydia is infection of the rectal lining with Chlamydia trachomatis, acquired through receptive anal intercourse. It is an extragenital infection — outside the genital tract — and is usually asymptomatic.
Do I need a rectal test if I only had anal sex?
Yes — if you have had receptive anal intercourse, rectal NAAT is the correct test. Urine testing does not detect rectal infection and will miss it entirely.
Is rectal chlamydia testing painful?
The swab is inserted a few centimeters into the rectum — most people find it mildly uncomfortable rather than painful. Self-collection is an option for those who prefer privacy.
Is rectal chlamydia curable?
Yes — doxycycline (100mg twice daily for 7 days) is preferred and highly effective. Azithromycin is less effective for rectal infection. Test-of-cure is recommended.
Why is doxycycline preferred over azithromycin for rectal chlamydia?
Azithromycin has inferior efficacy at the rectal site — cure rates are lower. Doxycycline achieves better eradication for extragenital chlamydia infections.
I have no symptoms — do I still need testing?
Yes — most rectal chlamydia is asymptomatic but still infectious. Testing is based on exposure risk, not symptoms. If you have had receptive anal sex, you should be tested.
Can I test myself?
Yes — self-collection of rectal swabs is acceptable and commonly done. The clinic provides instructions; the technique is simple and NAAT is accurate on self-collected specimens.
What other tests should I get?
If you have had receptive anal and oral sex, complete extragenital screening includes rectal and pharyngeal NAAT for chlamydia and gonorrhoea, plus urogenital testing and HIV/syphilis/hepatitis serology.
Is this confidential?
Yes — consultations, testing and results are strictly confidential. Services are MSM-inclusive and non-judgmental.
What if my partner has chlamydia?
If your partner was diagnosed with chlamydia and you have had receptive anal sex, you need rectal testing — the infection may be at that site even if genital testing is negative.
How much does rectal chlamydia testing cost?
Rectal NAAT typically costs Rs. 2,000–3,500. Complete extragenital screening with all sites and serology runs Rs. 6,000–9,000. Consultation is Rs. 450.
Still have questions? Contact us or book an appointment for personalized guidance.
Related Services & Guides
Chlamydia Guide
Complete chlamydia information — genital and extragenital.
Chlamydia Treatment
Treatment options including doxycycline for rectal infection.
Rectal Gonorrhea Test
Site-matched testing for rectal gonorrhoea.
Gonorrhea Testing
Complete gonorrhoea testing including extragenital.
LGBTQ Counseling
Inclusive, non-judgmental sexual health care.
Rectal Infection Specialist
Specialist care for rectal STIs.
Confidential STD Testing
Private, discreet STI testing.
STD Test Packages
Complete multi-site STI screening panels.
Related Health Guides
Medical Review & Sources
Medically reviewed by: Thamel Clinic Clinical Team (MBBS, MD)
Role: Sexual health and STI clinical reviewers, Thamel Clinic, Kathmandu
Last reviewed: 2026-11-08
Reviewed against current CDC STI Treatment Guidelines. This is general medical information; a registered clinician must assess each patient before treatment.
Medical information is general guidance only and does not replace an individual consultation. Treatment decisions are made after clinical assessment, including allergy and pregnancy review.
Medical Disclaimer
Important information about using this medical website
Educational Purpose Only
The information provided on this website, including all text, graphics, images, and other material, is for informational and educational purposes only. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment.
No Doctor-Patient Relationship
Use of this website does not create a doctor-patient relationship. The information provided is not tailored to your specific medical condition or health needs. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.
Emergency Situations
If you think you may have a medical emergency, call your doctor or emergency services immediately. In Nepal, call 102 for emergency services or go to the nearest hospital emergency room.
Emergency Contact Information:
National Emergency:
102 (Ambulance)
Our Clinic:
+977-9700682800 (WhatsApp available 24/7)
Bir Hospital Emergency:
+977-1-4412400
TU Teaching Hospital:
+977-1-4434320
Timeliness of Information
Medical information changes rapidly. While we strive to provide current and accurate information, we make no guarantees about the completeness, accuracy, reliability, suitability, or availability with respect to the website or the information contained on the website.
Professional Medical Advice Required
Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you have any specific questions about any medical matter, you should consult your doctor or other professional healthcare provider.
Treatment and Diagnosis
Do not use the information on this website to diagnose or treat any health problem or disease. The descriptions of treatments and medications provided are for general informational purposes only and do not constitute medical advice.
Limitation of Liability
In no event shall we be liable for any loss or damage arising from the use of this website or reliance on the information provided herein. This includes, but is not limited to, direct, indirect, incidental, punitive, and consequential damages.
Nepal-Specific Considerations
This website is operated in Nepal and is intended for users in Nepal. The medical information provided may not be applicable to healthcare systems outside Nepal. Always consult with local healthcare providers familiar with Nepal's healthcare system and regulations.
Last Updated: November 7, 2026 |Clinic: Thamel Clinic |Licensed: Registered